Comparative Pharmacology
Head-to-head clinical analysis: FOLOTYN versus OSIMERTINIB MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOLOTYN versus OSIMERTINIB MESYLATE.
FOLOTYN vs OSIMERTINIB MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FOLOTYN (pralatrexate) is a folate analogue metabolic inhibitor that competes for the reduced folate carrier and folylpolyglutamate synthetase, leading to intracellular accumulation of polyglutamated metabolites that inhibit dihydrofolate reductase (DHFR) and thymidylate synthase, thereby disrupting DNA synthesis and cell proliferation.
Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that selectively inhibits EGFR exon 19 deletion and L858R substitution mutations, as well as T790M resistance mutations, with less activity against wild-type EGFR.
3.0 mg/m2 intravenously over 3-5 minutes on days 1, 8, and 15 of a 28-day cycle.
80 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 4–6 hours; clinical context: supports weekly dosing schedule.
Terminal elimination half-life is approximately 48 hours (range 36-60 h) based on population pharmacokinetic analysis, supporting once-daily dosing.
Primarily renal excretion (approximately 80% of the dose recovered in urine over 24 hours, with about 60% as unchanged drug); biliary/fecal elimination accounts for <1%.
Osimertinib is eliminated primarily via feces (67.8%, with 1.2% as unchanged drug) and urine (13.8%, with 0.8% as unchanged drug). The remainder is recovered as metabolites.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent